Our Portfolio
Single asset
Seed
Neuroplastogen with novel target and mechanism of action able to induce neuroplasticity without psychedelics’ side effects
Platform
Seed
Targeted membrane protein degradation platform for oncology, auto-immune and inflammatory disorders
Platform
Seed
Small molecule platform inhibitors able to selectively degrade pathologic secreted and transmembrane proteins
Single asset
Incubation
Novel and differentiated RNA therapies to address the high unmet need in amyotrophic lateral sclerosis and fronto-temporal dementia
Immunology
Platform
Incubation
Cell specific in-vivo CAR-T approach to treat liquid/solid tumors, as well as autoimmune disorders
Rare disease
Platform
Incubation
Neuro-inflammation
Single asset
Incubation
Long-acting neurokine to modulate inflammation in the circulation and in the CNS
Single asset
Incubation
Disease modifier treatment activating the GFRa1/RET complex for the treatment of Parkinson's disease and other indications